Evidence map›Paper›PMID 32722438›Full record

SynthesisBiosensors2020

Electronic Nose as a Novel Method for Diagnosing Cancer: A Systematic Review.

Chiara Baldini, Lucia Billeci, Francesco Sansone, Raffaele Conte, Claudio Domenici, Alessandro Tonacci

Abstract readSystematic Review
In one paragraph

Synthesis in Biosensors, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 36 papers, 5 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
36citing papers in PubMed, 5 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

36 citing papers in PubMed, 5 syntheses or guidelines pooled it.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Pooled it
  5. Pooled it
  6. Accuracy of a new electronic nose for prostate cancer diagnosis in urine samples.International journal of urology : official journal of the Japanese Urological Association · 2022
    Trial
  7. Trial
  8. Review
  9. Article
  10. Article
  11. Review
  12. Article
  13. Review
  14. Review
  15. Article
  16. Review
  17. Review
  18. Article
  19. Urinary VOCs as biomarkers of early stage lung tumour development in mice.Cancer biomarkers : section A of Disease markers · 2024
    Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Chiara BaldiniSchool of Engineering, University of Pisa, Largo Lucio Lazzarino 1, 56122 Pisa, Italy.
Lucia BilleciInstitute of Clinical Physiology-National Research Council of Italy (IFC-CNR), Via Moruzzi 1, 56124 Pisa, Italy.ORCID 0000-0002-5487-0277
Francesco SansoneInstitute of Clinical Physiology-National Research Council of Italy (IFC-CNR), Via Moruzzi 1, 56124 Pisa, Italy.
Raffaele ConteInstitute of Clinical Physiology-National Research Council of Italy (IFC-CNR), Via Moruzzi 1, 56124 Pisa, Italy.
Claudio DomeniciInstitute of Clinical Physiology-National Research Council of Italy (IFC-CNR), Via Moruzzi 1, 56124 Pisa, Italy.
Alessandro TonacciInstitute of Clinical Physiology-National Research Council of Italy (IFC-CNR), Via Moruzzi 1, 56124 Pisa, Italy.ORCID 0000-0001-8335-5541

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Cancer is fast becoming the most important cause of death worldwide, its mortality being mostly caused by late or wrong diagnosis. Novel strategies have been developed to identify early signs of cancer in a minimally obtrusive way, including the Electronic Nose (E-Nose) technology, user-friendly, cost- and time-saving alternative to classical approaches. This systematic review, conducted under the PRISMA guidelines, identified 60 articles directly dealing with the E-Nose application in cancer research published up to 31 January 2020. Among these works, the vast majority reported successful E-Nose use for diagnosing Lung Cancer, showing promising results especially when employing the Aeonose tool, discriminating subjects with Lung Cancer from controls in more than 80% of individuals, in most studies. In order to tailor the main limitations of the proposed approach, including the application of the protocol to advanced stage of cancer, sample heterogeneity and massive confounders, future studies should be conducted on early stage patients, and on larger cohorts, as to better characterize the specific breathprint associated with the various subtypes of cancer. This would ultimately lead to a better and faster diagnosis and to earlier treatment, possibly reducing the burden associated to such conditions.

Indexed as

Electronic NoseBreath TestsHumansLung Neoplasmsartificial olfactioncancerelectronic nosehealthsensors

Identifiers

PMID32722438
PMCPMC7459473

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.